Search

Your search keyword '"Hisashi Sakamaki"' showing total 8 results
Start Over Author "Hisashi Sakamaki" Database Complementary Index
8 results on '"Hisashi Sakamaki"'

1. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.

Author

MAKI HAGIHARA, NORIYOSHI IRIYAMA, CHIKASHI YOSHIDA, HISASHI WAKITA, SHIGERU CHIBA, SHINICHIRO OKAMOTO, KIMIHIRO KAWAKAMI, NAOKI TAKEZAKO, TAKASHI KUMAGAI, KOITI INOKUCHI, KAZUMA OHYASHIKI, JUN TAGUCHI, SHINGO YANO, TADAHIKO IGARASHI, YASUJI KOUZAI, SATOSHI MORITA, JUNICHI SAKAMOTO, and HISASHI SAKAMAKI

Published
2016
Full Text
View/download PDF

2. A multicenter clinical study to determine the feasible initial doseof lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood stem-cell transplantation.

Author

MASAHIDE YAMAMOTO, KAZUTERU OHASHI, KAZUHIKO KAKIHANA, YUICHI NAKAMURA, TAKUYA KOMENO, HIROSHI KOJIMA, SATOSHI MORITA, and HISASHI SAKAMAKI

Subjects
MULTIPLE myeloma treatment, HEMATOPOIETIC stem cell transplantation, THALIDOMIDE, THERAPEUTICS
Abstract

Maintenance therapy with lenalidomide (LEN) for patients with multiple myeloma (MM) following autologous peripheral blood stem cell transplantation (auto-PBSCT) may be a promising option for preventing relapse or disease progression. However, the recommended dose of LEN has yet to be firmly established. We herein report the results of a multicenter clinical study for determining the feasible initial dose (FID) of LEN. In this trial, a total of 11 patients who achieved a very good partial response or complete response following auto-PBSCT were enrolled from five transplant centers in Japan. Three dose levels of LEN (level 0, 5 mg; level 1, 10 mg; and level 2, :15 mg) were tested in this study. FID was defined as the maximum estimated dose at which 70% of the patients could receive maintenance therapy for 12 weeks without any serious adverse events or disease progression. Using a continual reassessment method, 6 patients were assigned to level 0 and the remaining 5 patients were assigned to level 1. All 6 patients (100%) at level 0, but only 2 patients (40%) at level 1, completed 12 weeks of administration with their assigned dose of LEN. The results of our study demonstrated that, although 5 mg of LEN was acceptable in terms of safety, 7.5 mg of LEN may also be an acceptable FID. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

3. Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase.

Author

Koiti Inokuchi, Takashi Kumagai, Eri Matsuki, Kazuteru Ohashi, Atsushi Shinagawa, Yoshihiro Hatta, Jin Takeuchi, Chikashi Yoshida, Hisashi Wakita, Yasuji Kozai, Yukari Shirasugi, Shin Fujisawa, Osamu Iwase, Shingo Yano, Shinichiro Okamoto, Koji Oba, Junichi Sakamoto, and Hisashi Sakamaki

Published
2014
Full Text
View/download PDF

8. A randomized, postremission comparison of four courses of standard‐dose consolidation therapy without maintenance therapy versus three courses of standard‐dose consolidation with maintenance therapy in adults with acute myeloid leukemia: The Japan Adult Leukemia Study Group AML97 study

Author

Shuichi Miyawaki, Hisashi Sakamaki, Shigeki Ohtake, Nobuhiko Emi, Fumiharu Yagasaki, Kinuko Mitani, Shin Matsuda, Yuji Kishimoto, Yasushi Miyazaki, Norio Asou, Takafumi Matsushima, Masatomo Takahashi, Yoshiaki Ogawa, Sumihisa Honda, and Ryuzo Ohno

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results